HIV-1 resistance to dolutegravir: update and new insights

被引：0

作者：

Wainberg, Mark A. ^{[1
]}

Han, Ying-Shan ^{[1
]}

机构：

[1] McGill Univ, Jewish Gen Hosp, AIDS Ctr, Lady Davis Inst Med Res, Montreal, PQ, Canada

来源：

JOURNAL OF VIRUS ERADICATION | 2015年 / 1卷 / 01期

关键词：

drug resistance; viral fitness; R263K mutation;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Integrase strand transfer inhibitors (INSTIs) are the latest class of potent anti-HIV drugs. Currently, three INSTIs have been approved by the US Food and Drug Administration: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG). Resistance mutations to RAL and EVG emerge rapidly, and significant cross-resistance between these compounds has been documented. In addition, limited cross-resistance has been observed among DTG, a newer INSTI, and RAL and EVG even though clinical resistance to DTG, or mutations associated with DTG resistance in treatment-naive patients, has not yet been observed. This review summarises progress in studies on understanding resistance to DTG, mechanisms of possible resistance to DTG, and reasons for the absence of DTG-associated resistance mutations when the drug has been used in first-line therapy.

引用

页码：13 / 16

页数：4

共 50 条

[31] Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients
Rokx, Casper
Schurink, Carolina A. M.
Boucher, Charles A. B.
Rijnders, Bart J. A.
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (06) : 1632 - 1636
[32] The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir
Oliveira, Maureen
Mesplede, Thibault
Moisi, Daniela
Ibanescu, Ruxandra-Ilinca
Brenner, Bluma
Wainberg, Mark A.
[J]. AIDS, 2015, 29 (17) : 2255 - 2260
[33] Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance
Malet, Isabelle
Ambrosio, Francesca A.
Subra, Frederic
Herrmann, Beatrice
Leh, Herve
Bouger, Marie-Christine
Artese, Anna
Katlama, Christine
Talarico, Carmine
Romeo, Isabella
Alcaro, Stefano
Costa, Giosue
Deprez, Eric
Calvez, Vincent
Marcelin, Anne-Genevieve
Delelis, Olivier
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (05) : 1158 - 1166
[34] HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report
van Kampen, Jeroen J. A.
Pham, Hanh Thi
Yoo, Sunbin
Overmars, Ronald J.
Lungu, Cynthia
Mahmud, Rizwan
Schurink, Carolina A. M.
van Boheemen, Sander
Gruters, Rob A.
Fraaij, Pieter L. A.
Burger, David M.
Voermans, Jolanda J. C.
Rokx, Casper
van de Vijver, David A. M. C.
Mesplede, Thibault
[J]. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 31 : 323 - 327
[35] New patterns of HIV-1 resistance during HAART
Fumero, E
Podzamczer, D
[J]. CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (11) : 1077 - 1084
[36] Dolutegravir in acute HIV-1 infection: first reported case
Garibaldi, Franco
Pozzati, Marcia
Rodriguez, Claudia
Cecchini, Diego
[J]. REVISTA ESPANOLA DE QUIMIOTERAPIA, 2019, 32 (04) : 387 - 389
[37] Primary HIV-1 resistance - A new phase in the epidemic?
Pomerantz, RJ
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12): : 1177 - 1179
[38] Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics
DeAnda, Felix
Hightower, Kendra E.
Nolte, Robert T.
Hattori, Kazunari
Yoshinaga, Tomokazu
Kawasuji, Takashi
Underwood, Mark R.
[J]. PLOS ONE, 2013, 8 (10):
[39] The Humoral Response to HIV-1: New Insights, Renewed Focus
Alter, Galit
Moody, M. Anthony
[J]. JOURNAL OF INFECTIOUS DISEASES, 2010, 202 : S315 - S322
[40] HIV-1 diversity in Cameroon: new insights on the evolution of the virus
T Aime Marcel Simon
Z Lycias
M Eitel
W Carolyn
BA Wendy
MP Darren
[J]. Retrovirology, 9

← 1 2 3 4 5 →